PAVmed (PAVM) Q4 2025 earnings summary

Executive summary

• Diversified commercial-stage life sciences company with subsidiaries in medical devices, diagnostics, and digital health, focusing on innovative healthcare technologies.

• Key products include EsoGuard Esophageal DNA Test, EsoCheck Cell Collection Device, and the Veris Cancer Care Platform.

• Lucid Diagnostics and Veris Health are the main operating subsidiaries, with Lucid deconsolidated in September 2024 but still a significant equity investment.

Financial highlights

• Revenue for 2025 was $0.1 million, down from $3.0 million in 2024, mainly due to Lucid's deconsolidation.

• Net loss attributable to common stockholders was $3.8 million in 2025, compared to net income of $32.0 million in 2024 (which included a $72.3 million gain on Lucid deconsolidation).

• Cash on hand at year-end 2025 was $1.5 million; operating cash outflows were $5.2 million.

• Gross margin and operating expenses decreased significantly due to Lucid's deconsolidation.

Outlook and guidance

• Management expects continued operating losses and negative cash flows, with ongoing reliance on external financing.

• Substantial doubt exists about the company's ability to continue as a going concern without additional capital.

• Plans include further financings at both the parent and subsidiary levels, and efforts to increase revenues from Veris and secure Medicare coverage for EsoGuard.